PRISM BioLab (206A) · RiskRestated
Development of Similar Technologies and Competing Drugs by Other Companies
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Competition Risk from Candidate Product Introduction and Competing Products in the Pharmaceutical MarketA theme 20 companies write about · 22 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2025: 4 of 8 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 20 companies compared. The sentences above are computed from all 20.Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「Nevertheless, the possibility cannot be ruled out that large pharmaceutical companies with substantial financial resources may in the future synthesize compounds with novel structures or similar compounds after patent expiry.」
The possibility of major pharmaceutical companies and others developing similar technologies and compounds continued to be identified. - FY2024First statedAnnual report
「Nevertheless, the possibility cannot be ruled out that large pharmaceutical companies with substantial financial resources may in the future synthesize compounds with novel structures or similar compounds after patent expiry.」
The company cites the possibility that major pharmaceutical companies and biotech ventures will increasingly enter the market for PPI drug discovery as it expands.